Germany · Delayed Price · Currency is EUR Ocular Therapeutix Company Description
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA.
Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2006 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 274 |
| CEO | Pravin Dugel |
Contact Details
Address: 15 Crosby Drive Bedford, Delaware 01730 United States | |
| Phone | 781 357 4000 |
| Website | ocutx.com |
Stock Details
| Ticker Symbol | 0OT |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pravin Dugel | Chief Executive Officer |
| Donald Notman | Chief Financial Officer |
| Donald Notman | Chief Operating Officer |
| William Slattery | Head of Investor Relations |